Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results, Beats Estimates By $1.21 EPS

Arcturus Therapeutics (NASDAQ:ARCT) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $1.21, Yahoo Finance reports. The firm had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. During the same period in the prior year, the company posted ($1.98) earnings per share.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock traded up $0.20 during midday trading on Tuesday, hitting $19.99. 257,714 shares of the stock were exchanged, compared to its average volume of 513,220. Arcturus Therapeutics has a 1 year low of $17.52 and a 1 year high of $45.00. The firm has a market cap of $538.37 million, a P/E ratio of -5.26 and a beta of 2.64. The company has a 50 day moving average price of $27.52 and a two-hundred day moving average price of $31.09.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the sale, the chief operating officer now owns 447,448 shares in the company, valued at $17,902,394.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 13.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have recently commented on ARCT. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Tuesday. Canaccord Genuity Group decreased their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a report on Tuesday, July 2nd. Finally, William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $67.60.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.